A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
<p>Abstract</p> <p>Background</p> <p>There are no previous reports of paliperidone palmitate's (PP) long term tolerability or pharmacokinetics of the highest dose in patients with schizophrenia. This study evaluates safety and tolerability, as well as pharmacokinet...
Main Authors: | Coppola Danielle, Liu Yanning, Gopal Srihari, Remmerie Bart, Samtani Mahesh N, Hough David W, Nuamah Isaac, Sulaiman Ahmad, Pandina Gahan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-244X/12/26 |
Similar Items
-
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
by: Coppola, Danielle, et al.
Published: (2012) -
Alternative initiation regimen of paliperidone palmitate long-acting injectable
by: I.E. Menendez Gil, et al.
Published: (2022-06-01) -
A case of tardive dyskinesia with paliperidone palmitate
by: Philip Kumar Boyanapally, et al.
Published: (2015-01-01) -
Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
by: Emsley R, et al.
Published: (2018-01-01) -
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018-10-01)